AI has advanced from pilot programs into real biopharma workflows. But has it lived up to the hype? Drawing from an expert call with Dr. Paul Agapow, former director of data science at GSK, this report dissects whether AI is on track to make drug development faster, cheaper, and more successful. Learn how AI is reshaping drug development in real time, turning AI execution into a key competitive differentiator.
AI in Drug Development 2026: From Experimentation to Execution
About the Authors
Sara Mallatt, Director of Healthcare Research
Sara has more than 18 years of experience generating sell-side research content across a variety of industries. Prior to joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara holds a bachelor’s degree in journalism and a master’s in industrial engineering. She works from her home in Missoula, Montana.
Sean Carmichael
Sean is a Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.
Explore more
Key Debates Transforming Technology, Media, and Telecom in 2026
In this report, we harness broker research, Tegus Expert Insights, and company commentary in AlphaSense to explore how the debates below are shaping the technology, media, and telecom landscape in 2026.
Key Debates Transforming Energy and Industrials in 2026
In this report, we harness broker research, Tegus Expert Insights, and company commentary in AlphaSense to explore how eight debates are shaping the energy and industrials landscape in 2026.
The Future of Primary Research: An Evolution of AI-Driven Expert Insights
In this report, we explore the evolution of expert research as AI-driven enhancements streamline inefficiencies and bottlenecks, creating asynchronous workflows. As access proliferates and AI enables faster synthesis, it is increasingly essential for investment teams to harness complete ecosystems to drive high-stakes decisions with conviction.
Transform intelligence
into advantage
Develop bold strategies, seize opportunities, and lead with clarity and confidence.